The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains

Virology

Volumn 364, Issue 2, 2007, Pages 486-493

  Bogerd, Hal P ^a   Wiegand, Heather L ^a   Doehle, Brian P ^a   Cullen, Bryan R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

APOBEC3G; DNA editing; HIV 1; Intrinsic immunity

Indexed keywords

CYTIDINE DEAMINASE; MUTANT PROTEIN; VIRUS DNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; VIRION; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANTI-RETROVIRAL AGENTS; CELL LINE; CYTIDINE DEAMINASE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; NUCLEOSIDE DEAMINASES; PROTEIN STRUCTURE, TERTIARY; REPRESSOR PROTEINS; RNA EDITING; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 34249892197     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.03.019     Document Type: Article

References (44)

1. Alce T.M., and Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279 (2004) 34083-34086
2. Beale R.C.L., Petersen-Mahrt S.K., Watt I.N., Harris R.S., Rada C., and Neuberger M.S. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337 (2004) 585-596
3. Betts L., Xiang S., Short S.A., Wolfenden R., and Carter Jr. C.W. Cytidine deaminase. The 2·3 Å crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 235 (1994) 635-656
4. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.-J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 (2004) 1392-1396
5. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 (2006) 8450-8458
6. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., and Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34 (2006) 89-95
7. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., and Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8780-8785
8. Cen S., Guo F., Niu M., Saadatmand J., Deflassieux J., and Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279 (2004) 33177-33184
9. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., and Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 (2006) 480-485
10. Chesebro B., Wehrly K., Nishio J., and Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66 (1992) 6547-6554
11. Conticello S.G., Harris R.S., and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13 (2003) 2009-2013
12. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80 (2006) 1067-1076
13. Dang Y., Wang X., Esselman W.J., and Zheng Y.-H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 (2006) 10522-10533
14. Doehle B.P., Schäfer A., and Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339 (2005) 281-288
15. Haché G., Liddament M.T., and Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280 (2005) 10920-10924
16. Hakata Y., and Landau N.R. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J. Biol. Chem. 281 (2006) 36624-36631
17. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
18. Holmes R.K., Koning F.A., Bishop K.N., and Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: comparisons with APOBEC3G. J. Biol. Chem. 282 (2007) 2587-2595
19. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., and Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (2002) 285-296
20. Jónsson S.R., Haché G., Stenglein M.D., Fahrenkrug S.C., Andrésdóttir V., and Harris R.S. Evolutionarily conserved and non-conserved retrovirus restruction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34 (2006) 5683-5694
21. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., and Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79 (2005) 5870-5874
22. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
23. Liu B., Sarkis P.T.N., Luo K., Yu Y., and Yu X.-F. Regulation of APOBEC3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79 (2005) 9579-9587
24. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
25. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9 (2003) 1398-1403
26. Mehle A., Strack B., Ancuta P., Zhang C., McPike M.N., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2004) 7792-7798
27. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Löwer J., Cichutek K., Flory E., Schumann G.G., and Münk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem 281 (2006) 22161-22172
28. Navarro F., Bollman B., Chen H., König R., Yu Q., Chiles K., and Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2005) 374-386
29. Newman E.N.C., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., and Sheehy A.M. Anti-viral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
30. OhAinle M., Kerns J.A., Malik H.S., and Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80 (2006) 3853-3862
31. Schäfer A., Bogerd H.P., and Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328 (2004) 163-168
32. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
33. Sheehy A.M., Gaddis N.C., and Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
34. Shindo, K., Takaori-Kondo, A., Kobayashi, M., Abudu, A., Fukunaga, K., Uchiyama T. 2003, The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. 278, 44412-44416.
35. Stenglein M.D., and Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281 (2006) 16837-16841
36. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
37. Suspène R., Sommer P., Henry M., Ferris S., Guétard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., and Vartanian J.-P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32 (2004) 2421-2429
38. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
39. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.-F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
40. Yu Q., Chen D., König R., Mariani R., Unutmaz D., and Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 (2004) 53379-53386
41. Yu Q., König R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 (2004) 435-442
42. Zennou V., Perez-Caballero D., Göttlinger H., and Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78 (2004) 12058-12061
43. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
44. Zheng Y.-H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 6073-6076